The FDA is responding to criticism of drug manufacturers' direct-to-consumer advertising, a $4.1 billion industry in 2004, by launching a review of drug marketing. The review, which will examine issues such as the balance of drugs' risks and benefits in ads, the development and enforcement of guidelines, and the use of digital media, will begin with a public meeting to gather information and opinions.

Related Summaries